CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets
CSL Limited (ASX: CSL) heads into the final stretch of 2025 with its share price still under pressure—but with a growing stack of “things that matter” piling up beneath the surface: a sizeable on‑market buyback steadily absorbing stock, a major US manufacturing investment designed to reinforce its plasma-therapy moat, and a high-profile strategic reset that’s trying to simplify a complex, three‑engine biotech into something the market can price with less guesswork. As of the most recent trading day (Friday, 19 December 2025), CSL shares closed at A$175.08, after a volatile month that saw the stock slide from the mid‑A$180s toward